Arbutus Biopharma (ABUS) Research & Development (2016 - 2025)
Historic Research & Development for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $5.8 million.
- Arbutus Biopharma's Research & Development fell 5951.8% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 5374.34%. This contributed to the annual value of $54.0 million for FY2024, which is 2667.98% down from last year.
- According to the latest figures from Q3 2025, Arbutus Biopharma's Research & Development is $5.8 million, which was down 5951.8% from $5.5 million recorded in Q2 2025.
- Arbutus Biopharma's 5-year Research & Development high stood at $22.9 million for Q4 2022, and its period low was $5.5 million during Q2 2025.
- Moreover, its 5-year median value for Research & Development was $16.7 million (2021), whereas its average is $15.7 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 5096.99% in 2021, then crashed by 6464.54% in 2025.
- Quarter analysis of 5 years shows Arbutus Biopharma's Research & Development stood at $19.2 million in 2021, then rose by 19.45% to $22.9 million in 2022, then fell by 23.47% to $17.6 million in 2023, then crashed by 49.84% to $8.8 million in 2024, then plummeted by 34.42% to $5.8 million in 2025.
- Its Research & Development was $5.8 million in Q3 2025, compared to $5.5 million in Q2 2025 and $9.0 million in Q1 2025.